INCB057643 clinical trials
Also written INCB057643.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses INCB057643 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INCB057643
- 4
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test INCB057643.
- Apr 2027Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsPhase 1 · Incyte Corporation
Studies
Open first, then newest update. How each study uses INCB057643 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingPhase 1Incyte CorporationNCT04279847Written as INCB057643
- Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)TerminatedPhase 1/2Incyte CorporationNCT02959437Written as INCB057643
- Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02711137Written as INCB057643
- A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06941077Written as INCB057643
Codes
What other systems call INCB057643 · ClinicalTrials.gg INT001512
- MeSH (NLM) C000712522INCB057643One source NLM
- UNII (FDA) H5212R2DPMSX-682Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712522 | INCB057643 | One source NLM |
| UNII (FDA) | H5212R2DPM | SX-682 | Confirmed FDA, NLM |
Also registered as incb-057643 (UNII 87TZD0JEBS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.